Abstract

SILVARINO, Ricardo et al. Autosomal dominant polycystic kidney disease. Who can benefit from tolvaptan therapy? State of the art. Rev. Méd. Urug. [online]. 2022, vol.38, n.3, e401.  Epub Sep 01, 2022. ISSN 0303-3295.  https://doi.org/10.29193/rmu.38.3.11.

Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease. It is characterized by the progressive appearance of renal cysts that usually lead to extreme chronic kidney disease in adulthood. The approval of the use of tolvaptán (V2 vasopressin receptor antagonist) has meant a significant change in the treatment of this disease. In recent years, evidence has proved the benefits of initiating treatment with tolvaptán in patients with a rapidly evolving disease. A descriptive review of the main clinical studies published in 2012-2022 period is carried out and a useful scheme is suggested to select those patients who can benefit from the start of treatment.

Keywords : Autosomal dominant polycystic kidney; Chronic kidney disease; Tolvaptan.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )